214 related articles for article (PubMed ID: 25816330)
21. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
22. Histological evaluation of nintedanib in non-alcoholic steatohepatitis mice.
Susutlertpanya W; Wakuda H; Otani N; Kuramoto T; Li L; Kuranari M; Sekiguchi A; Kudo H; Uchida T; Imai H; Uemura N
Life Sci; 2019 Jul; 228():251-257. PubMed ID: 31078545
[TBL] [Abstract][Full Text] [Related]
23. Role of chronic inflammation in the pathogenesis of nonalcoholic steatohepatitis: lessons from a unique mouse model using melanocortin receptor-deficient mice.
Itoh M; Suganami T; Ogawa Y
Endocr J; 2021 Jul; 68(7):743-749. PubMed ID: 33967185
[TBL] [Abstract][Full Text] [Related]
24. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
[TBL] [Abstract][Full Text] [Related]
25. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
[TBL] [Abstract][Full Text] [Related]
26. Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholic steatohepatitis and liver fibrosis in mice.
Motiño O; Agra N; Brea Contreras R; Domínguez-Moreno M; García-Monzón C; Vargas-Castrillón J; Carnovale CE; Boscá L; Casado M; Mayoral R; Valdecantos MP; Valverde ÁM; Francés DE; Martín-Sanz P
Biochim Biophys Acta; 2016 Sep; 1862(9):1710-23. PubMed ID: 27321932
[TBL] [Abstract][Full Text] [Related]
27. Gliptins Suppress Inflammatory Macrophage Activation to Mitigate Inflammation, Fibrosis, Oxidative Stress, and Vascular Dysfunction in Models of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Wang X; Hausding M; Weng SY; Kim YO; Steven S; Klein T; Daiber A; Schuppan D
Antioxid Redox Signal; 2018 Jan; 28(2):87-109. PubMed ID: 28635324
[TBL] [Abstract][Full Text] [Related]
28. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis.
Asano T; Watanabe K; Kubota N; Gunji T; Omata M; Kadowaki T; Ohnishi S
J Gastroenterol Hepatol; 2009 Oct; 24(10):1669-76. PubMed ID: 19788607
[TBL] [Abstract][Full Text] [Related]
29. Enzymatically-epoxidized docosahexaenoic acid, 19,20-EpDPE, suppresses hepatic crown-like structure formation and nonalcoholic steatohepatitis fibrosis through GPR120.
Aoki H; Isobe Y; Yoshida M; Kang JX; Maekawa M; Arita M
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Mar; 1868(3):159275. PubMed ID: 36566874
[TBL] [Abstract][Full Text] [Related]
30. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
Ishii H; Horie Y; Ohshima S; Anezaki Y; Kinoshita N; Dohmen T; Kataoka E; Sato W; Goto T; Sasaki J; Sasaki T; Watanabe S; Suzuki A; Ohnishi H
J Hepatol; 2009 Mar; 50(3):562-71. PubMed ID: 19162361
[TBL] [Abstract][Full Text] [Related]
31. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
32. Human amnion epithelial cells and their soluble factors reduce liver fibrosis in murine non-alcoholic steatohepatitis.
Kuk N; Hodge A; Sun Y; Correia J; Alhomrani M; Samuel C; Moore G; Lim R; Sievert W
J Gastroenterol Hepatol; 2019 Aug; 34(8):1441-1449. PubMed ID: 30821873
[TBL] [Abstract][Full Text] [Related]
33. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
34. Adipose tissue-derived stem cells prevent fibrosis in murine steatohepatitis by suppressing IL-17-mediated inflammation.
Yamato M; Sakai Y; Mochida H; Kawaguchi K; Takamura M; Usui S; Seki A; Mizukoshi E; Yamashita T; Yamashita T; Ishida K; Nasti A; Tuyen HTB; Komura T; Yoshida K; Wada T; Honda M; Kaneko S
J Gastroenterol Hepatol; 2019 Aug; 34(8):1432-1440. PubMed ID: 30828861
[TBL] [Abstract][Full Text] [Related]
35. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
36. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
37. Roles of Macrophages in Advanced Liver Fibrosis, Identified Using a Newly Established Mouse Model of Diet-Induced Non-Alcoholic Steatohepatitis.
Tada Y; Kasai K; Makiuchi N; Igarashi N; Kani K; Takano S; Honda H; Yanagibashi T; Watanabe Y; Usui-Kawanishi F; Furusawa Y; Ichimura-Shimizu M; Tabuchi Y; Takatsu K; Tsuneyama K; Nagai Y
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36362037
[TBL] [Abstract][Full Text] [Related]
38. The Ethanol Extract from Lonicera japonica Thunb. Regresses Nonalcoholic Steatohepatitis in a Methionine- and Choline-Deficient Diet-Fed Animal Model.
Tzeng TF; Tzeng YC; Cheng YJ; Liou SS; Liu IM
Nutrients; 2015 Oct; 7(10):8670-84. PubMed ID: 26506376
[TBL] [Abstract][Full Text] [Related]
39. Synthesized HMGB1 peptide prevents the progression of inflammation, steatosis, fibrosis, and tumor occurrence in a non-alcoholic steatohepatitis mouse model.
Ishii Y; Tsuchiya A; Natsui K; Koseki Y; Takeda N; Tomiyoshi K; Yamazaki F; Yoshida Y; Shimbo T; Tamai K; Terai S
Hepatol Res; 2022 Dec; 52(12):985-997. PubMed ID: 35932481
[TBL] [Abstract][Full Text] [Related]
40. Blocking sphingosine 1-phosphate receptor 2 accelerates hepatocellular carcinoma progression in a mouse model of NASH.
Yoshida T; Tsuchiya A; Kumagai M; Takeuchi S; Nojiri S; Watanabe T; Ogawa M; Itoh M; Takamura M; Suganami T; Ogawa Y; Terai S
Biochem Biophys Res Commun; 2020 Oct; 530(4):665-672. PubMed ID: 32768187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
